Arch Oncology is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. Our next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.
Our lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, we are advancing a number of pipeline programs, including anti-signal regulatory protein (SIRP) antibodies. Our leadership team has successfully developed new drugs for patients before and we are backed by leading investors, including RiverVest Venture Partners, Roche Venture Fund, 3x5 RiverVest Partners II-B, and Lightchain.